-
Advocates meet with CT lawmakers to ask for support with Alzheimer's disease
The Alzheimer’s Association of Connecticut is bringing light to a disease to affects 80,000 people living in the state. On Wednesday, advocates met with legislators to share stories and ask for support.
-
FDA will take a deeper look into the safety and effectiveness of Lilly experimental Alzheimer's drug
Federal regulators are putting off a decision on Eli Lilly’s potential Alzheimer’s treatment with an unusual request to have an advisory committee examine the drug. Lilly expected a decision on donanemab in this year’s first quarter, which ends this month.
-
Biogen will stop selling its controversial Alzheimer's drug Aduhelm
Biogen will stop selling its Alzheimer’s treatment Aduhelm. The drug was once seen as a potential blockbuster but it stumbled after its launch a few years ago.
-
State police launch registry to help find people with dementia when they go missing
Connecticut State Police have partnered with the Connecticut chapter of the Alzheimer’s Association to launch a registry to help find people with dementia who go missing.
-
After US approval, Japan approves Leqembi, its first Alzheimer's drug
Japan’s health ministry has approved Leqembi, a drug for Alzheimer’s decease that was jointly developed by Japanese and U.S. pharmaceutical companies.
-
Campaign aims to raise Alzheimer's awareness in Hispanic communities
Latinos are 1.5 times more likely to develop Alzheimer’s than other races, according to the Alzheimer’s Association.
-
10 possible signs of Alzheimer's — and how the disease affects Hispanic people
The Alzheimer’s Association created a list of early signs of the disease or other types of dementia. In the United States, the disease disproportionately affects Hispanic patients.
-
Bob Barker died from Alzheimer's disease, death certificate states
Barker died at age 99 from Alzheimer’s disease and other contributing factors, as outlined in his death certificate.
-
Some insurers won't cover new Alzheimer's treatment shown to slow decline
Some private insurers are balking at paying for the first drug fully approved to slow mental decline in Alzheimer’s patients.
-
Study shows Eli Lilly's Alzheimer's drug slows memory decline but with safety risks
If U.S. regulators approve, the drug would be only the second Alzheimer’s treatment convincingly shown to delay the mind-robbing disease — after rival Leqembi. Both drugs pose a serious safety concern — brain swelling and bleeding.
-
FDA approves Alzheimer's drug Leqembi, paving way for broader Medicare coverage
Leqembi slowed cognitive decline in a clinical trial, but the treatment is expensive and carries serious risks of brain swelling and bleeding.
-
Alzheimer's drug gets FDA panel's backing, setting the stage for broader use
U.S. health advisers are backing the full approval of an Alzheimer’s drug that received preliminary approval last year. A panel of advisers to the Food and Drug Administration on Friday voted in favor of the infused medication from drugmakers Eisai and Biogen. The FDA granted accelerated approval in January based on early results suggesting the drug could modestly slow Alzheimer’s....
-
Medicare Details Plan to Cover Alzheimer's Treatments
Patients will have to participate in registries that collect real-world data on how the drug works as a condition of coverage.
-
Experimental Drug Slows Worsening Effects of Alzheimer's
Eli Lilly and Co. said Wednesday its experimental Alzheimer’s drug appeared to slow worsening of the mind-robbing disease in a large study. NBC 5’s Bianca Castro talked with Frisco neurologist Dr. Aimee Garza about how it works.
-
Eli Lilly Says Experimental Drug Slows Alzheimer's Worsening
Eli Lilly and Co. says its experimental Alzheimer’s drug appears to slow worsening of the mind-robbing disease after an 18-month trial.
-
Alzheimer's: Medicare Will Cover Leqembi for All Patients If FDA Approves Drug, CMS Chief Says
Medicare has severely restricted access to the medication Leqembi, which costs $26,500 per year, because the FDA approved it just on an expedited basis.
-
Eli Lilly Says Experimental Alzheimer's Drug Reduces Brain Plaque in Early Study
Eli Lilly said a higher dose of the up-and-coming Alzheimer’s treatment remternetug had a larger effect on clearing amyloid plaque.
-
Alzheimer's ‘Escapees': Scientists Seek Clues From Those Who Evade Genetic Fate
Scientists are digging into why a few people escape the rarest form of Alzheimer’s, which is inherited and strikes young. Every so often, someone dodges their family’s genetic fate.
-
Report: Growing Burdens for Alzheimer's Family Caregivers
Inside the numbers of the Alzheimer’s Association’s latest report, and how Connecticut families face caregiving challenges.
-
Why a New Alzheimer's Drug Is Having a Slow US Debut
The first drug to show that it slows Alzheimer’s is on sale, but treatment for most patients is still several months away. Experts say scant coverage of the drug and a long setup time needed by health systems are two main factors behind the slow debut. The U.S. Food and Drug Administration approved Leqembi from Japanese drugmaker Eisai in early...